Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peguricase with methotrexate in refractory gout
NCT06298071Phase 1Recruiting
- Sponsor
- Shanghai Institute of Biological Products
- Start
- Mar 2023
- Primary completion
- Dec 2026
- Modality
- Metabolic Enzymes, Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of peguricase in gout (3 arms), sponsored by Shanghai Institute of Biological Products. Primary endpoints: Adverse Events at 14 weeks, Serious Adverse Events at 14 weeks and 7 more. Started Mar 2023; status: recruiting.
02
Drugs
peguricase
03
Conditions
gout
Beyond the preview
Go deeper on NCT06298071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06298071.